After 10 h treatment of breast cancer cells, wedelolactone reduced chymotrypsin-like proteasome activity measured in cell extracts, with reported IC50 values of 27.8 μM in MDA-MB-231, 12.78 μM in MDA-MB-468 and 19.45 μM in T47D cells. These values describe proteasome activity after exposure, rather than cell killing. [2]
RANKL-associated NF-κB and NFATc1 signaling in RAW264.7 cells
Cell-based study · Mouse pre-osteoclastic RAW264.7 cells stimulated with RANKL [1]
Wedelolactone reduced RANKL-associated p65 phosphorylation, c-Fos and c-Src protein levels, and nuclear localization of NFATc1. These pathway readouts do not establish direct IKK binding or exclusive IKK dependence.
Literature-Reported Treatment Conditions
- Treatment concentration
- 1.25, 2.5 and 5 μg/ml for Figure 4A; 2.5 μg/ml for Figure 4B
- Exposure duration
- 6 d
- Method
- Exposure in culture medium; Western blot and NFATc1 immunofluorescence/nuclear fraction analysis
- Co-treatment
- 30 ng/ml RANKL; comparisons include RANKL-only and unstimulated controls
- Reported limits
- Vehicle composition is not specified in the read Materials/cell assay methods. Replicate type is not defined beyond n=3 in the caption; no viability control for these signaling readouts was identified in the read sections.
Methods and source locations
Compound reported in the paper: Wedelolactone; Compound label in the paper: Wed
Evidence concerns the named compound used by the authors; equivalence of Adooq lots was not tested.
Figure 4A-B; corresponding Results; Materials and osteoclastogenesis, immunofluorescence and Western blot methods
p65 phosphorylation and c-Fos/c-Src protein levels: Immunoblotting with total p65 and GAPDH controls; no exact densitometry estimated from bars — Figure 4A and caption; osteoclast signaling Results
Nuclear localization of NFATc1: Immunofluorescence and nuclear/cytosolic immunoblotting; histone and GAPDH fraction controls — Figure 4B and caption; osteoclast signaling Results
Inhibition of purified 20S and 26S proteasome activity
Biochemical assay · 26S proteasome purified from human MDA-MB-231 cells; commercially supplied bovine 20S proteasome [2]
Wedelolactone inhibited substrate cleavage by isolated proteasomes, with the strongest reported activity against the chymotrypsin-like endpoint. This is an additional biochemical activity and does not establish IKK specificity.
Literature-Reported Treatment Conditions
- Treatment concentration
- 5, 10, 25, 50 and 100 μM wedelolactone (Figure 2 legend)
- Exposure duration
- 1 h at 37 °C
- Method
- Fluorogenic substrate cleavage by 5 μg purified 26S or 10 nM bovine 20S proteasome; 50 μM substrate
- Vehicle
- DMSO negative control; final DMSO fraction not specified
- Co-treatment
- 10 μM MG132 positive control in separate assay mixtures
- Reported limits
- Confidence intervals for fitted IC50 values and final DMSO percentage not reported in the read sections; no compound fluorescence-interference counterscreen identified there.
Methods and source locations
Compound reported in the paper: Wedelolactone; Compound label in the paper: w
Evidence concerns the named compound used by the authors; equivalence of Adooq lots was not tested.
Results 2.2; Figure 2A-B and caption; Methods 4.1, 4.3.1-4.3.2, 4.10
Chymotrypsin-like activity of purified 26S proteasome: Suc-LLVY-AMC cleavage; nonlinear regression (GraphPad PRISM 6); Figure 2: three independent experiments, mean ± SD — Results 2.2; Figure 2A; Methods 4.3.2 and 4.10
Chymotrypsin-like activity of bovine 20S proteasome: Suc-LLVY-AMC cleavage; nonlinear regression; Figure 2: three independent experiments, mean ± SD — Results 2.2; Figure 2B; Methods 4.3.2 and 4.10
Proteasome activity after wedelolactone exposure in breast cancer cells
Cell-based study · Human MDA-MB-231, MDA-MB-468 and T47D breast cancer cell lines [2]
After 10 h exposure, lysates showed decreased proteasome substrate cleavage. Chymotrypsin-like IC50 values differed across the three cell lines. These are proteasome-activity endpoints after cell treatment, not cytotoxicity IC50 values.
Literature-Reported Treatment Conditions
- Treatment concentration
- 5, 10, 25, 50 and 100 μM wedelolactone (Figure 1 legend)
- Exposure duration
- 10 h cell exposure; lysate substrate cleavage measured for 1 h at 37 °C
- Method
- 50 μg cell extract with 50 μM fluorogenic substrate; chymotrypsin-like endpoint uses Suc-LLVY-AMC
- Vehicle
- DMSO-treated control; final DMSO fraction not specified
- Co-treatment
- 10 μM MG132 positive-control treatment in separate cultures
- Reported limits
- Fitted IC50 confidence intervals and final DMSO percentage not reported in the read sections; viability-normalized target engagement is not established by this lysate activity assay.
Methods and source locations
Compound reported in the paper: Wedelolactone; Compound label in the paper: w
Evidence concerns the named compound used by the authors; equivalence of Adooq lots was not tested.
Results 2.1; Figure 1A-C and caption; Methods 4.1-4.3.3 and 4.10
Chymotrypsin-like proteasome activity after cell treatment: Cell-extract Suc-LLVY-AMC cleavage; nonlinear regression; three independent experiments, mean ± SD — Results 2.1; Figure 1A-C and caption; Methods 4.3.3 and 4.10